StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
MGRX$0.42-2.28%
Fair $0.42+0.0%

MGRX

Mangoceuticals, Inc.

Healthcare / Health Information ServicesNasdaqCM

$0.42

-0.01 (-2.28%)

Fairly Valued+0.0%Fair Value $0.42Fund rank 27/100 · Data gapFallback financials|
SA 24/D
F-Score: 2/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $-5.9M · quality 50.3/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 14/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

24/100

D

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years ROE is -1.4%, below the 5% threshold
Thesis & Journal · MGRXLocal privado en este navegador · Mangoceuticals, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$7M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-135.8%

↓

Gross Margin

54.9%

↑

Debt/Equity

0.02

↓
52-Week Range$0
$0$3

TradingView lightweight chart

MGRX price, volumen y niveles de valoración

Último $0.420Periodo -99.3%
Fair value: $0.420

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+270.9%

FCF CAGR

—

FCF margin

-1282.9%

FCF / Net income

0.28x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $456021.0 · net income $-20.6M · FCF $-5.9M

2022-FY → 2025-FY

Gross margin

54.9%+0.7% pts

Operating margin

-4200.5%+18079.2% pts

Net margin

-4526.8%+17825.3% pts

FCF margin

-1282.9%+14262.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$456021.00$456021.00$615873.00$731493.00$8939.00
Net Income$-20.6M$-20.6M$-8.7M$-9.2M$-2.0M
EBITDA$-18.8M$-18.8M$-8.0M$-9.1M$-2.0M
EPS-2.17-2.17-4.80-8.58-1.96
Gross Margin54.9%54.9%61.7%59.0%54.3%
Operating Margin-4200.5%-4200.5%-1411.6%-1260.3%-22279.7%
Net Margin-4526.8%-4526.8%-1413.6%-1259.4%-22352.1%
Balance Sheet
Debt/Equity0.020.020.020.170.57
Current Ratio0.290.29———
Cash Flow
Free Cash Flow$-5.9M$-5.9M$-4.9M$-7.0M$-1.4M
Returns
ROE-135.8%-135.8%-62.4%-1189.1%-325.4%
Valuation
P/B0.280.280.355.41—
Growth & Yield
Revenue Growth-26.0%-26.0%-15.8%8083.2%—
EPS Growth54.8%54.8%44.1%-338.4%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -80.7%

Total return

-80.7%

Start / end P/E

n/dx → n/dx

EPS bridge

-4.80 → -2.17

Residual

-80.7%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-80.7%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.